February 2016
-
Story From Our Labs
Opening chemistry education to the world
Novartis taps MOOC technology to share chemistry education with the world
-
Story Discovery
Neuroscientists restore cell-to-cell signaling and sociability in autism models
Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.
-
Featured News
How digital technologies are creating a “new normal” for people living with COPD
Learn how Novartis is working with chronic obstructive pulmonary disease (COPD) patients to develop digital health technologies that help them find their “new normal.”
-
Story Discovery
Novartis and Pfizer join forces to upend oncology dogma
Industry labs find that, contrary to earlier evidence, KRAS-driven tumors are not addicted to autophagy.
January 2016
-
Press release
Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination
2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease New strategy from the Novartis Foundation to accelerate… -
Press release
Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
Strong growth (cc) in full year sales, core operating income and core EPS[2] Net sales up 5% (cc) and core operating income up 10% (cc) Core operating income margin up 1.3 percentage points (… -
Press release
Novartis a enregistré, en 2015, une forte croissance des ventes et une hausse de sa marge core (tcc1) et annonce des plans pour accélérer la croissance d'Alcon et rationaliser les opérations du Groupe
Forte croissance (tcc) des ventes, du résultat opérationnel core et du BPA core[2] en 2015 Chiffre d'affaires net en hausse de 5% (tcc) et résultat opérationnel core en augmentation de 10% (tcc… -
Press release
Novartis erzielt 2015 eine kräftige Steigerung des Umsatzes und der Kern-gewinnmarge (kWk[1]); Pläne zur Wachstumsbeschleunigung bei Alcon und zur Straffung der Konzernaktivitäten bekannt gegeben
Solides Wachstum (kWk) beim Umsatz, operativen Kernergebnis und Kerngewinn pro Aktie[2] im Gesamtjahr Der Nettoumsatz steigt um 5% (kWk), das operative Kernergebnis wächst um 10% (kWk) Die… -
Story Discovery
Rare speed on a rare disease
An investigational treatment for an uncommon immunodeficiency disease races into clinical studies.
-
Featured News
Novartis moves to address superbug threat
Novartis and other industry leaders call for action to address antimicrobial resistance, one of the world’s most serious public health challenges
-
Story From Our Labs
How to address the culture gap between academia and industry in biomedicine
Experts call for significant changes to facilitate the discovery of new treatments.
-
Press release
Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
Cosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) FDA approval for Cosentyx is…